Last reviewed · How we verify

NCT05835635: CABO-LA

Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine

Not yet recruiting Last updated 7 November 2024
What this trial tests

trial in Patient Satisfaction in 50 participants. Not yet recruiting.

Timeline
1 May 2025
Primary endpoint
1 December 2025
1 May 2026

Quick facts

Lead sponsorPontificia Universidad Catolica de Chile
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment50
Start date1 May 2025
Primary completion1 December 2025
Estimated completion1 May 2026
Sites1 location across Chile

Conditions studied

Sponsor

Pontificia Universidad Catolica de Chile — full company profile →

Who can join

18 and older, any sex, with Patient Satisfaction or Patient Preference. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This protocol will assess the level of satisfaction, acceptance of treatment and quality of life of patients with undetectable HIV who voluntarily change from oral to injectable antiretroviral treatment at 72 weeks of follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Patient Satisfaction

Currently open trials in the same condition.

Other Pontificia Universidad Catolica de Chile trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05835635.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing